Ophthalmology and therapy · 2026
Safety and Feasibility of the Exchange Procedure for the Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Berdahl John P, Lehmann Robert P, Jones Jason J, Sarkisian Steven R, Applegate David, Katz L Jay, Kothe Angela C, Navratil Tomas
Аннотация
INTRODUCTION: We conducted a prospective, single-arm, open-label study to evaluate the feasibility and safety of an exchange procedure for the travoprost intracameral implant.
METHODS: Adult subjects with open-angle glaucoma or ocular hypertension who had previously received a travoprost intracameral implant were enrolled at 12 sites in the United States and one in the Philippines. Subjects were administered a new travoprost intracameral implant followed by removal of the previous implant ("exchange" procedure). The primary outcome measures were treatment-emergent adverse events, and other ocular safety parameters (i.e., endothelial cell density, visual acuity, slit-lamp biomicroscopy, and visual fields).
RESULTS: Thirty-three subjects who had received a travoprost intracameral implant for a mean duration of 4.2 years prior were recruited. All subjects were successfully implanted with a new implant, and the previous implant was successfully removed. There were no treatment-related serious adverse events, or severe treatment-related adverse events in the eye that underwent the exchange procedure. No subject required a subsequent explantation.
CONCLUSIONS: Travoprost intracameral implant demonstrated an acceptable safety profile both during and after the exchange procedure, supporting its re-administration.
CLINICALTRIALS: gov NCT04615403.
METHODS: Adult subjects with open-angle glaucoma or ocular hypertension who had previously received a travoprost intracameral implant were enrolled at 12 sites in the United States and one in the Philippines. Subjects were administered a new travoprost intracameral implant followed by removal of the previous implant ("exchange" procedure). The primary outcome measures were treatment-emergent adverse events, and other ocular safety parameters (i.e., endothelial cell density, visual acuity, slit-lamp biomicroscopy, and visual fields).
RESULTS: Thirty-three subjects who had received a travoprost intracameral implant for a mean duration of 4.2 years prior were recruited. All subjects were successfully implanted with a new implant, and the previous implant was successfully removed. There were no treatment-related serious adverse events, or severe treatment-related adverse events in the eye that underwent the exchange procedure. No subject required a subsequent explantation.
CONCLUSIONS: Travoprost intracameral implant demonstrated an acceptable safety profile both during and after the exchange procedure, supporting its re-administration.
CLINICALTRIALS: gov NCT04615403.